Modulation of neuronal dopamine levels in diseases such as tardive dyskinesia
, Tourette syndrome, Huntington's chorea, schizophrenia, and tardive dystonia, which are characterized, in part, by a hyperdopaminergic state, should provide symptomatic benefits for patients with these diseases.
Motor symptoms of schizophrenia: is tardive dyskinesia
a symptom or side effect?
- Pipeline Review, H1 2015 report provides an overview of the Dyskinesia
's therapeutic pipeline.
Morningside's investment in Synchroneuron demonstrates our belief in the potential of SNC-102 to safely and effectively treat neuropsychiatric disorders such as tardive dyskinesia
as well as its potential in additional indications, said Gerald Chan, Chairman of Morningside Technology Ventures.
Although no patients on any second-generation drug developed new symptoms of dystonia or dyskinesia
, a few on haloperidol developed dyskinesia
Anxiety was related to moderate to severe lower right extremity dyskinesia
Now experts led by a team at Cardiff University have identified how an overactive system within nerve cells can lead the development of dyskinesia
results in involuntary movements which can mean people's bodies distort or their arms or legs jerk uncontrollably.
These ultrastructural features are consistent with complete ciliary aplasia which is a rare form of primary ciliary dyskinesia
is a rare and permanent side-effect of neuroleptic drugs, which include some of the older antipsychotics as well as some old-fashioned anti-nausea drugs.
Istradefylline reduces dyskinesia
, or involuntary body movements, resulting from long-term treatment with classical anti-parkinson's drugs such as levodopa.
The agency is evaluating data from the Stalevo Reduction in Dyskinesia
Evaluation--Parkinson's Disease (STR1DE-PD) study, which found that over a mean of almost 3 years, the number of prostate cancers diagnosed among the men treated with entacapone, carbidopa, and levodopa (marketed as Stalevo) was about four times higher than the cases diagnosed among those treated with the carbidopa and levodopa combination product (marketed as Sinemet).
Biovail acquires the US and Canadian rights to develop and commercialize the drug for the treatment of Dyskinesia
in Parkinson's Disease.
The same neural systems that control decreased movement are also involved in conditions of increased, purposeless movement such as dyskinesia
(Suilleabhain & Giller 2003).
A boxed warning about an increased risk of tardive dyskinesia
associated with the chronic use of metoclopramide will be added to the drug's label, according to the Food and Drug Administration.